Prostate cancer, lung cancer, and ccRCC have all been studied using monoclonal antibodies that target different immune checkpoint inhibitors (such as CTLA4, PDCD1, and LAG3) [39]. This evidence concerns the gene PDCD1 and prostate carcinoma.